Overactive bladder
Conditions
Interventions
Imidafenacin 0.1mg is orally administered to the patients with overactive bladder twice a day, after the breakfast and supper.
Solifenacin Succinate 5mg is orally administered to the patients with ove
Sponsors
GAP Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with Q3 score of Overactive Bladder Symptom Score (OABSS) >=2 and the total score >=3. (2) 20 years old or more outpatient (3) Written consent with participation in this examination will be enrolled.
Exclusion criteria
Exclusion criteria: (1) Genuine stress incontinence. (2) Prostate cancer, bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis. (3) Indwelling or intermittent urethral catheterization. (4) Polyuria. (5) Lower urinary tract symptom is unstable. (6) Serious heart failure, serious liver failure and serious kidney failure. (7) Contraindications to antimusucarinic agents. (8) Sjogren's syndrome or hyposalivation by RT. (9) Treatment with banned medicine within 2 weeks before the run-in period. (10) Electric stimulation therapy or bladder training within 3 months before the run-in period. (11) Genitourinary surgery within 6 months before the run-in period. (12) Any other cases who are regarded as inadequate for study enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After 4 weeks, 8 weeks, 12 weeks of treatment, the efficacy ( Overactive Bladder Symptom Score (OABSS)) will be evaluated. | — |
Secondary
| Measure | Time frame |
|---|---|
| After 4 weeks, 8 weeks, 12 weeks of treatment, Dry Mouth symptom and Constipation symptom will be evaluated. | — |
Countries
Japan
Outcome results
None listed